RecruitingEarly Phase 1NCT06693284
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
Studying Malignant peripheral nerve sheath tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Minnesota
- Principal Investigator
- Robert Galvin, MDUniversity of Minnesota
- Intervention
- mirdametinib and vorinostat(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06693284 on ClinicalTrials.govOther trials for Malignant peripheral nerve sheath tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04872543A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT04222413Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT03872427Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyNational Cancer Institute (NCI)
- RECRUITINGNANCT03141021Multi-Institutional Registry for Malignant Peripheral Nerve Sheath TumorsWashington University School of Medicine
See all trials for Malignant peripheral nerve sheath tumor →